57 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25654260	49	Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.	F. Hoffmann-La Roche
25642985	45	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.	University of Strasburg
24874785	333	New, potent, and selective peptidic oxytocin receptor agonists.	Ferring Research Institute
16250654	41	2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.	Glaxosmithkline
21700453	56	Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.	Msd
21458261	55	The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.	Msd
21146408	53	The characterization of a novel V1b antagonist lead series.	Glaxosmithkline
20674355	58	Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.	Glaxosmithkline
19081251	38	Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.	Glaxosmithkline
22984902	59	Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.	University of Strasburg
22239250	59	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.	Glaxosmithkline
22425346	28	Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.	Emory University
19800231	92	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.	Schering-Plough Research Institute
18032036	17	The discovery of GSK221149A: a potent and selective oxytocin antagonist.	Glaxosmithkline
17850055	18	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.	Institute Genomics Functional (Igf)
17300166	88	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.	University of Montpellier
16302826	129	Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.	Serono Pharmaceutical Research Institute
15084136	96	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.	Medical College of Ohio
12036367	46	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.	University of Montpellier
22249122	9	Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.	Lehigh University
21688787	295	New, potent, selective, and short-acting peptidic V1a receptor agonists.	Ferring Research Institute
21605973	69	Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.	Abbott Laboratories
21601454	26	Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.	Msd
21596563	33	Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.	Msd
21428295	43	Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.	University of Montpellier
21353540	55	Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.	Msd
20550119	96	Oral oxytocin antagonists.	Drugmoldesign
20719508	26	Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.	Ligand Pharmaceuticals
18778939	23	Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.	Pfizer
12502367	17	New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.	Université
31022340	101	Discovery of Potent, Selective, and Short-Acting Peptidic V	Ferring Research Institute
30896946	36	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.	Tohoku University and Department of Pharmaceutical Sciences
31229420	21	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.	Kanazawa University
10197974	22	Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.	University of Montpellier
31223461	56	Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.	Shanghai Hengrui Pharmaceutical
31850759	24	Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects.	Calibr At The Scripps Research Institute
30098866	30	Novel, potent, selective and brain penetrant vasopressin 1b receptor antagonists.	Abbvie Deutschland
30199637	172	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.	Umr7200 Cnrs/Universit£
29602673	49	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.	Imperial College
17221184	55	Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.	Columbia University
12660315	17	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.	Lcg Bioscience
12649361	779	L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.	Case Western Reserve University
12192085	52	Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.	Case Western Reserve University
12110997	380	In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.	WestfÄLische Wilhelms-UniversitÄ
11861823	10	Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.	Sanofi-Synthelabo Recherche
11512051	80	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.	Case Western Reserve University
9864265	14	OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.	Second Tokushima Institute of New Drug Research
9454810	72	SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.	Sanofi Recherche
9223568	38	Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.	Yamanouchi Pharmaceutical